Clinical Trial Search

Primary: The Number of Patients With Dose-Limiting Toxicities (DLTs) in the First Course of Each Treatment Arm — 4; 4; 2 Participants

Primary: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 53.3; 66.7 percentage of participants

Primary: Percentage of Participants Experiencing an Adverse Event (AE) — 66.7; 66.7; 33.3 Percentage of Participants

Primary: Steady-State Concentration (Css) (48-168) Profile for LNG — 1256; 1246; 1384 pg/mL

Primary: Reduction in Post-traumatic Stress Reaction Symptoms Among Participants — 11.79; 11.80; 12.17; 10.03 units on a scale

Primary: Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine — 53.9; 54.6 µM*hr

Primary: Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 0.5 Hour Post-Dose — 404.09; 408.92…

Primary: Maximum Measured Concentration of BI 695501 in Plasma (Cmax) — 3.79; 3.48 Micro-gram (µg) per milliliter (mL)

Primary: Maximum Tolerated Dose (MTD) of Eribulin Mesylate — 1.4 mg/m^2

Primary: Percentage of Patients With Dose Limiting Toxicity During the First Treatment Cycle in Phase Ia Part of the Study — 0; 0; 0; 0 Percentage of participants

Primary: Area Under the Plasma Concentration-time Curve From Time of Dose Extrapolated to Infinite Time (AUC[0-infinity]) of DTG for Part 1 — 58900; 58400 hours*nanograms/mL…

Primary: Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol — 132; 143 pg/mL

Primary: AUC (0-48 Hours) — 168603.588; 181152; 411826.811; 427355.99 picogram per ml / hour

Primary: Dose Limiting Toxicity (DLT) - Percentage of Participants With DLT Events — 1 Participants

Primary: Area Under the Plasma Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC[0-t])…